Journal of Virology, February 2001, p. 1095-1103, Vol. 75, No. 3
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.3.1095-1103.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Hématologie Expérimentale, Institut J. Bordet, 1000 Brussels,1 and Centre d'Etude et de Recherches Vétérinaires et Agrochimiques, 1180 Uccle,3 Belgium; Veterinary Infectious Disease Organization, Saskatoon, Saskatchewan, Canada2; and Centre de Thérapie Génique, Institut Paoli-Calmettes, Marseille, France4
Received 22 June 2000/Accepted 25 October 2000
| |
ABSTRACT |
|---|
|
|
|---|
Bovine leukemia virus (BLV) is closely associated with the
development of B-cell leukemia and lymphoma in cattle. BLV infection has also been studied extensively in an in vivo ovine model that provides a unique system for studying B-cell leukemogenesis. There is
no evidence that BLV can directly infect ovine B cells in vitro, and
there are no direct data regarding the oncogenic potential of the viral
Tax transactivator in B cells. Therefore, we developed ovine B-cell
culture systems to study the interaction between BLV and its natural
target, the B cell. In this study, we used murine CD154 (CD40 ligand)
and
-chain-common cytokines to support the growth of B cells
isolated from ovine lymphoid tissues. Integrated provirus,
extrachromosomal forms, and viral transcripts were detected in
BLV-exposed populations of immature, rapidly dividing surface immunoglobulin M-positive B cells from sheep ileal Peyer's patches and
also in activated mature B cells isolated from blood. Conclusive evidence of direct B-cell infection by BLV was obtained through the use
of cloned B cells derived from sheep jejunal Peyer's patches. Finally,
inoculation of sheep with BLV-infected cultures proved that infectious
virus was shed from in vitro-infected B cells. Collectively, these data
confirm that a variety of ovine B-cell populations can support
productive infection by BLV. The development of ovine B-cell cultures
permissive for BLV infection provides a controlled system for
investigating B-cell leukemogenic processes and the pathogenesis of BLV infection.
| |
INTRODUCTION |
|---|
|
|
|---|
Bovine leukemia virus (BLV) is a B-lymphotropic retrovirus that is associated with B-cell lymphoproliferative disorders in cattle (2, 22). Infection can either remain asymptomatic or result in persistent lymphocytosis, characterized by an increased number of circulating B lymphocytes and, more rarely, by clonal lymphoid tumors after a long latency period. Under experimental conditions, BLV can infect sheep and induces B-cell neoplasia at very high frequencies (26).
Structurally and functionally, BLV is related to human T-cell lymphotropic viruses type 1 and 2 (HTLV-1 and HTLV-2), which infect T cells and are associated with adult T-cell leukemia, tropical spastic paraparesis, and hairy T-cell leukemia in humans (11, 38, 51). BLV, HTLV-1 and HTLV-2 have a similar genomic organization, encode gene products with biologically similar functions, and share mechanisms of transactivation (10). Aside from the structural genes (gag, pol, and env), the BLV provirus contains a region, X, which encodes at least four auxiliary proteins, Tax, Rex, R3, and G4. Tax and Rex are involved in transcriptional and posttranscriptional regulation of viral expression, respectively, and are essential for viral infectivity in vivo (5, 9). R3 and G4 may play a role in virus propagation in the infected host (48), and G4 was shown to have moderate oncogenic potential in vitro (21).
The BLV provirus integrates into bovine and ovine B cells, and this
viral infection may result in B-cell transformation. In cattle,
infected cells have been reported as mature, CD5+ surface
immunoglobulin M-positive (sIgM+) and CD5+
sIgG+ B cells (27, 45). In sheep, BLV-infected
cells from aleukemic animals were found to be either CD5+
or CD5
, Cd11b+ sIgM+ B cells
(1, 31, 32, 37, 42, 43), and cells isolated from lymphoma
and leukemic tissues were consistently sIgM+ B cells. It
has also been suggested that BLV may infect other cell types, including
granulocytes, monocytes, and CD8+ T cells (7, 19,
39). However, Mirsky et al. (29) did not obtain
convincing evidence that either monocytes or T cells contained BLV provirus.
BLV infection has been studied extensively in an in vivo ovine model using whole blood, blood leukocytes, fresh or cultured lymphocytes from BLV-seropositive animals, and the injection of proviral DNA (26, 33, 40, 41, 49, 50). It is possible to establish tumor-derived B-cell lines from BLV-infected sheep, and these cell lines, with integrated provirus, provide a unique system for studying B-cell leukemogenic processes (23, 41, 42). Furthermore, a variety of cell types have been used to study BLV infection and viral gene expression (6, 7, 28, 37). Both the HTLV-1 and BLV Tax proteins exhibit oncogenic potential, based on immortalization and transformation assays with rat embryonic fibroblasts (35, 46). It has not been possible, however, to perform similar studies with either bovine or ovine B cells due to an inability to culture primary B cells or establish permanent B-cell lines.
Therefore, we sought to develop an ovine B-cell culture system as a
model to study the interaction between BLV and its natural target, the
B cell. The first culture system used was a pure population of
immature, sIgM+ B cells from the lymphoid follicles of
sheep ileal Peyer's patches (12). The culture of these
ileal Peyer's patch follicular B cells (iPfB cells) is limited by
extensive cell death during the first 24 to 48 h after isolation.
Cocultivation of iPfB cells with murine CD154 (CD40 ligand) inhibits
much of this cell death, induces cytokine responsiveness, and
specifically supports B-cell growth (14). Thus, it is
possible to maintain pure cultures of sheep B cells for prolonged
periods using CD154 coculture in conjunction with
-chain-common
cytokines (13). In this study, we used these culture
conditions to maintain the growth of B cells isolated from different
ovine lymphoid tissues and provide the first experimental evidence that
a variety of cultured B-cell populations can support productive
infection by BLV.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals and tissues. The sheep used for the isolation of B cells were Suffolk lambs obtained from the Department of Animal and Poultry Science, University of Saskatchewan, Saskatoon, Canada. Ileal Peyer's patch tissue was collected from 6- to 8-week-old lambs within 15 min after a lethal intravenous injection of Euthanyl (MTC Pharmaceuticals Ltd.). Tissue was collected and handled as described previously (12). Blood was collected from 6- to 12-month-old lambs using the procedure described previously (8). Sheep that were inoculated intradermally with cultured cells were maintained in isolation at the Centre d'Etude et de Recherches Vétérinaires et Agrochimiques (Brussels, Belgium). Animals were injected at 6 months of age with 107 cells collected from the different B-cell cultures, and blood and sera were then collected from each sheep at weekly intervals for the next year. Anti-p24 serum antibody titers were determined with a competitive enzyme-linked immunosorbent assay as previously described (33). For detection of BLV provirus, 10-ml samples of total blood were frozen and used for PCR amplification as previously described (40).
Cells and media.
OVK (ovine kidney) cells, an uninfected
cell line, and FLK, a BLV-infected fetal lamb kidney cell line
(44), were grown in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum (FBS) (Gibco), 1 mM sodium
pyruvate, 2 mM glutamine, nonessential amino acids, and kanamycin (100 µg/ml). YR2 is a latently infected, Tax-deficient ovine B-cell line
that was established from leukemic B cells isolated from a BLV-infected
sheep (23, 41). YR2LTaxSN is a BLV-producing
B-cell line resulting from retrovirus vector-mediated tax
gene transfer into native YR2 cells (40). M267 is a clonal
lymphoma-derived B-cell line isolated from a BLV-infected sheep. The
B-cell lines were maintained in Optimem medium (Gibco) supplemented
with 10% FBS and additives as described for adherent cell lines. J558L
cells expressing murine CD154 were maintained and used for coculture
with sheep B cells as described previously (14). Griebel
and Ferrari (14) confirmed that there was a specific
interaction between murine CD154 and CD40 expressed on sheep B cells.
Clone 2 (sIgM+) and clone 4 (sIgG1+) B-cell
clones were established from the jejunal Peyer's patch of a lamb by
limiting-dilution culture following long-term coculture with CD154 and
recombinant human interleukin-2 (IL-2), IL-4, IL-7, and IL-15
(15). The culture medium for cloned Peyer's patch B
cells, freshly isolated iPfB cells, and blood lymphocytes was AIM-V
(Gibco-BRL) supplemented with 2% FBS and 2 × 10
5 M
-mercaptoethanol (Sigma). Blood lymphocytes were cocultured with
CD154 and recombinant human IL-2 in a manner similar to that described
for iPfB cells (14). Recombinant human IL-2, IL-4, IL-7
and IL-15 were purchased from Peprotech EC (London, U.K.), and each
cytokine was used at a final concentration of 10 ng/ml. All cell
cultures were incubated at 37°C in a 5% CO2 humidified atmosphere. Viable cells were identified by trypan blue dye exclusion or propidium iodide exclusion (2.5 µg/ml), and cell number was counted with a hemacytometer or a Coulter particle counter.
Proliferation assays with 2 × 105 cells/well were
conducted in flat-bottomed 96-well tissue culture plates (Falcon) in a
final volume of 200 µl. During the last 4 h of a 72-h incubation
period, the cultures were pulsed with 0.4 µCi of
[3H]thymidine (Amersham). [3H]thymidine
incorporation was determined using standard methods for cell harvesting
and liquid scintillation counting.
BLV infection of ovine B-cell cultures. BLV-producing FLK cells were seeded at 106 cells in 100-mm culture dishes with 10 ml of medium and cultured for 48 h. Cloned FLK proviruses were shown to be infectious in vitro and in vivo (37). Expression of viral capsid protein is a marker for late-stage expression, when full-length and singly spliced transcripts are translated into the structural proteins that are assembled into virions (34). Flow cytometric analysis of intracellular p24 confirmed that the majority of FLK cells were producing viral proteins, and a competitive enzyme-linked immunosorbent assay (33) determined that supernatants collected from 48-h-cultured FLK cells contained 850 ng of p24 per ml (data not shown). For all in vitro infection assays, 10 × 106 B cells/well were incubated in a six-well plate with 1 ml of cell-free culture supernatant from either FLK or OVK cells in a final culture volume of 5 ml. After a 96-h infection period, the B cells were collected, washed with phosphate-buffered saline, and transferred to new cultures with fresh medium and the appropriate costimulation.
Southern blot analysis. High-molecular-weight cellular DNA was prepared by 0.05% sodium dodecyl sulfate (SDS) and pronase (0.2 mg/ml) disruption of cells, followed by extraction with phenol-chloroform and ethanol precipitation. Genomic DNA was analyzed by Southern blot as previously described (40). The nylon-bound digested DNA was hybridized with a 32P-labeled 8.3-kb SacI full-length BLV probe (4 × 108 to 5 × 108 cpm/ml) (41). The amount of hybridized sequence was quantified by PhosphoImager analysis (Molecular Dynamics) or conventional autoradiography.
Primers for PCR. The sequences of the BLV primers used in PCR experiments were as follows; nucleotide positions according to Sagata (38) are shown in parentheses, and 5' long terminal repeat (LTR) positions are given for primers located in the LTR region: Tax1 sense (7321 to 7340), 5'-GATGCCTGGTGCCCCCTCTG-3'; Tax2 antisense (7604 to 7623), 5'-ACCGTCGCTAGAGGCCGAGG-3'; EnvA sense (4766 to 4788): 5'-TCCTGGCTACTAACCCCCCCGT-3'; EnvB antisense (5756 to 5777), 5'-TCCAGTGAGCCCCACTGACAGG-3'; LTRA sense (1 to 22), 5'-TGTATGAAAGATCATGCAGGCC-3'; LTRC antisense (577 to 599), 5'-GCCGCCGAGGGGGTGGGTCCAGA-3'; U5 sense (470 to 490), 5'-TTCTCGCGGCCCGCGCTCTCT-3'; and U3 antisense (415 to 434), 5'-GCCAGACGCCCTTGGAGCGC-3'.
For the detection of BLV-specific mRNA, three different primers were used; the numbers indicating their positions in the genome correspond to the sequence of BLV-FLK (38). To detect full-length gag-pol (8.4 kb) and singly spliced env (4.4 kb) BLV mRNAs, a primer upstream of the second splice donor, EnvA (described above) was used with primer EnvC (4921 to 4942) (5'-CCTAGGGACAGGGAGCATCTCC-3'), located downstream of the second splice donor site but upstream of the second splice acceptor site, into the second intron. EnvA was used as a 5' primer with Can2 (7314 to 7333) (5'-GGCACCAGGCATCGATGGTG-3') as the complementary primer for the detection of the 2.1-kb doubly spliced tax/rex mRNA. Can2 is located downstream of the second splice junction.DNA PCR. Genomic DNA was amplified in 100-µl reaction mixtures containing 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM KCl, 0.2 mM deoxynucleoside triphosphates, 0.5 µM each primer, and 1 U of Taq polymerase (Roche). The amplification sequence consisted of a 5-min step at 94°C, 36 cycles of 1 min at 94°C, 1 min at 60°C, and 2 min at 72°C, and a 10-min step at 72°C.
RNA PCR. For reverse transcription (RT)-PCR experiments, total RNA was extracted using Tripure reagent according to the manufacturer's protocol (Roche) and treated for 1 h at 37°C with 40 U of DNase I (Promega). Then 1 µg of RNA was reverse transcribed and amplified using the Titan RT-PCR system according to the standard protocol supplied by the manufacturer (Roche).
Flow cytometry.
The phenotype of cells in all B-cell
cultures was analyzed prior to collecting cell pellets to analyze
proviral integration and viral expression. B cells were identified with
monoclonal antibodies specific for the following surface antigens: IgM
(PIg45A clone), IgG1 (BIg715A clone), and major histocompatibility
complex (MHC) class II (TH14B clone) (VMRD Inc., Pullman, Wash.). CD72 (DU2-104 clone) was a generous gift from Wayne Hein, Wallaceville Animal Research Center, Upper Hut, New Zealand. T cells were identified with monoclonal antibodies specific for CD5 (clone ST1a), CD4 (clone
17D-13), CD8 (clone E95), and 
TCR (clone 86D). Cell labeling and
analysis were done as described previously (16). For the detection of intracellular BLV p24, the cells were permeabilized with
Permeafix (Ortho Diagnostics), incubated with anti-p24 monoclonal antibodies (clones 4H6, 4'F3, 7G6, 3B1, 2'C1, 4'G9, 2B1, and 5F7; provided by D. Portetelle, Facultés universitaires Sciences
agronomiques Gembloux, Belgium), and monoclonal antibody binding was
detected with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Sigma), as previously described (40).
Statistical analysis. Statistical analyses were performed using GraphPad Prism 2.01 software (Graphpad Software, Inc., San Diego, Calif.). Differences among groups were determined using a one-way analysis of variance and Tukey's multiple comparison test if the analysis of variance revealed a significant difference (P < 0.05) among groups. Data are presented as the mean and 1 standard deviation (SD) of values from three experiments.
| |
RESULTS |
|---|
|
|
|---|
BLV infection of iFpB cells.
To determine whether BLV could
infect ovine B cells in vitro, we first used a pure B-cell population
isolated from lymphoid follicles of the ileal Peyer's patch (iPfB
cells) of sheep (12). IPfB cells are a relatively
homogeneous population of immature, sIgM+ B cells
(18) with 35 to 40% of freshly isolated cells in S phase
(17). The permissiveness of the host cell to many and perhaps all oncoretroviruses is cell cycle dependent, and
infection of growth-arrested cells appears to be unique to lentiviruses in the retrovirus family (25). Therefore it was
deemed most appropriate to select a B-cell target population with a
high mitotic index. In the first experiment, iPfB cells were incubated
with FLK (BLV-positive) or OVK (BLV-negative) culture supernatants added to culture medium alone or medium supplemented with recombinant human IL-2 and IL-4. Viable-cell numbers were determined, and cell
pellets were collected for analysis of provirus integration and viral
gene expression at 24 and 96 h postinfection (p.i.). These
cultures are hereafter referred to as short-term iPfB-cell cultures. In
the absence of exogenous cytokines, viable iPfB-cell number decreased
rapidly, with most B cells dead within 6 days after exposure to either
OVK or FLK culture supernatant. In contrast, with the addition of
exogenous human IL-2 and IL-4, FLK-exposed iPfB-cell cultures displayed
a significantly (P < 0.05) increased number of viable
cells relative to OVK-exposed cultures (Fig. 1A). The level of
[3H]thymidine incorporation, however, was not
significantly different for viable cells collected from FLK- and
OVK-exposed iPfB cultures (Fig. 1B). These observations suggested that
BLV infection and costimulation with exogenous IL-2 and IL-4 might
enhance iPfB-cell survival.
|
|
|
-chain-common cytokines. These culture
conditions had previously been shown to specifically block iPfB-cell
death and induce a sustained B-cell proliferative response
(13). The iPfB-cell cultures were maintained by
transferring the cells every 3 to 4 days p.i. to fresh medium and
restimulating with CD154 and cytokines. These iPfB-cell cultures are
referred to as cytokine/CD154 iPfB-cell cultures. CD154 and exogenous
cytokines supported the growth of iPfB cells, but in addition, there
was a significant increase (P < 0.01) in the number of
viable cells present in the FLK-exposed cultures (Fig.
4A). [3H]thymidine
incorporation assays indicated that BLV infection increased the number
of viable CD154-stimulated iPfB cells through a significant
(P < 0.05) increase in cell proliferation (Fig. 4B).
Thus, the effect of BLV infection on B-cell growth or survival appeared
to be modulated by exogenous cytokines and other cosignals (Fig. 1 and
4).
|
|
|
BLV infection of B cells from blood.
BLV infection in sheep
most frequently results in B-cell leukemia. Therefore, we investigated
whether it was possible to also infect B cells present in blood.
Freshly isolated blood mononuclear cells were incubated with either
BLV-negative OVK or BLV-positive FLK culture supernatant for 96 h.
These cultures are hereafter referred to as L-2 and BL-2 cultures,
respectively. To support the specific growth of blood B cells, it was
necessary to cocultivate blood lymphocytes with murine CD154 and
recombinant human IL-2. Blood mononuclear cells were passaged and
restimulated every 3 to 4 days p.i. Following a 3-week culture period,
flow cytometric analysis revealed that over 97% of viable cells were B
cells (CD72+, MHC class II+, and either
sIgM+ or sIgG1+), and there were no detectable
T cells (CD4+, CD8+, or 
TCR+)
(data not shown).
BLV infection of jejunal Peyer's patch B-cell clones. The experiments with B cells cultured from ileal Peyer's patch and blood indicated that B cells were permissive for BLV infection. However, the initial cultures from blood contain numerous monocytes (8), and macrophages and mesenchymal cells are present in cell suspensions prepared from ileal Peyer's patch lymphoid follicles (12). Therefore, it was possible that the initial BLV infection in these cultures involved cells other than B lymphocytes. To conclusively prove that BLV infection and viral expression can involve only B cells, we used two cloned B-cell populations derived from the jejunal Peyer's patch of a lamb (15). Furthermore, we chose an sIgM+ (clone 2) and an sIgG1+ (clone 4) B-cell clone to determine if the state of B-cell differentiation restricted BLV infection.
Clone 2 and clone 4 cells were exposed for 96 h to culture supernatant from either FLK or OVK cells. The presence of proviral DNA, nonintegrated circular forms, and BLV transcripts was evaluated by PCR and RT-PCR in cell pellets collected at days 10, 20, and 48 p.i. These analyses revealed that the provirus was present and transcribed in both the clone 2 (sIgM+) and the clone 4 (sIgG+) FLK-exposed B cells. Southern blot analysis of SacI DNA digests suggested that approximately 1 of every 10 cells had integrated provirus. The results from samples collected at day 48 p.i. are shown in Fig. 3A, 3B, 5, and 6. There was no significant difference in viable B-cell number when the growth of BLV-infected cells was compared to that of uninfected (OVK supernatant) B-cell clones (data not shown). Thus, BLV infection in approximately 10% of B cells did not have a significant impact on the growth of these cloned B-cell populations. In conclusion, by using cloned B cells, we clearly demonstrated that BLV can directly infect ovine B cells. Furthermore, we determined that BLV replication can occur in a pure B-cell population and that viral transcription is T-cell independent. Also, by using clone 2 (sIgM+) and clone 4 (sIgG+) B cells, we demonstrated that in vitro BLV infection is not limited to sIgM+ B cells.Production of infectious virus by infected B cells.
The above
results analyzed viral replication and transcription but did not
address the production of functional viral particles. To determine if
the B cells infected in vitro with BLV were productively infected, we
used an in vivo infection assay (40). This experimental approach is the most sensitive method for studying BLV infectivity (26, 40, 41, 48, 49). Furthermore, the in vivo ovine model
is unique, because it allows us to address questions regarding retrovirus pathogenesis in a true biological context. Briefly, sheep
were inoculated intradermally with 107 cells from each of
the B-cell cultures (two animals per cell type for FLK-exposed B cells
and one animal per cell type for control, OVK-exposed B cells). All
animals injected with FLK-exposed B cells seroconverted within 2 to 3 weeks, whereas control animals remained seronegative. Similarly, PCR
analysis with BLV-specific primers indicated that all sheep inoculated
with FLK-exposed B cells had detectable provirus in blood by 3 weeks
after injection (Fig. 7). Furthermore,
blood samples were collected for over 1 year, and both antibody titers
and BLV provirus loads increased gradually throughout this period (data
not shown). These observations clearly demonstrated that the
FLK-exposed B cells were productively infected by BLV. Since the
initial in vitro infection was mediated though a cell-free viral
supernatant procedure and not by a cocultivation strategy, there was no
possibility of virus transmission by contaminating FLK cells. In
conclusion, the in vivo experiments clearly demonstrated that B cells
derived from a variety of ovine lymphoid tissues were productively
infected in vitro by BLV.
|
| |
DISCUSSION |
|---|
|
|
|---|
The present investigation is the first demonstration of an in vitro culture system to examine B-cell infection by BLV. Integrated and extrachromosomal provirus forms were detected following BLV infection of ovine B cells isolated from a variety of lymphoid tissues. Furthermore, the presence of viral transcripts was demonstrated using RT-PCR, and in vivo infection experiments clearly demonstrated that infected B cells produced infectious virus. Finally, conclusive evidence of direct B-cell infection by BLV was obtained through the use of cloned B-cell populations. Collectively, these data confirmed that ovine B cells isolated from a variety of lymphoid tissues were productively infected in vitro with BLV.
The initial analysis of BLV-infected iPfB cells was limited by
extensive apoptotic cell death and increased nuclease activity in these
short-term cultures (30). The high mitotic index in these
cultures, however, might have facilitated proviral integration. In
fact, a high level of cell proliferation occurs in all ovine B-cell
cultures costimulated with murine CD154 and exogenous
-chain-common cytokines (12). This CD154 costimulation system was used
to further investigate the permissiveness of B cells from blood and jejunal Peyer's patches to BLV infection. From these experiments, it
was evident that BLV could infect not only the immature, rapidly dividing B cells present in ileal Peyer's patch but also the activated B cells isolated from blood and jejunal Peyer's patches.
PCR amplification revealed that all FLK-exposed B cells had detectable provirus, whatever the culture conditions and the length of the culture period. Evidence of provirus integration was provided by Southern blot experiments with restricted genomic DNA. Provirus load was consistently low, as expected following in vitro infection with viral supernatants. Despite the fact that this infection method is not as efficient as a cocultivation procedure, it was used to eliminate the possibility of detecting viral sequences from contaminating FLK producer cells. If it is assumed that each infected cell contained a single copy of provirus, then approximately 10 to 20% of cultured B cells had integrated provirus. This estimation of infected-cell frequency was based on integrated provirus forms, since much lower levels of circular, nonintegrated DNA are usually present during the course of a retroviral infection (3).
Circular extrachromosomal DNA is considered a marker of active viral replication and is always present during the acute phase of an in vitro or in vivo infection (reviewed in reference 3). We used a PCR method to specifically detect this form in the presence of both integrated and linear nonintegrated viral DNA (36). This PCR analysis detected circular extrachromosomal DNA in all BLV-infected B-cell cultures and provided evidence that viral replication was occurring in these cells. Although circular DNA is transcriptionally active, its integrated counterpart is a more efficient template for transcription and possesses a much longer half-life. Thus, the majority of viral mRNA necessary to produce viral proteins and, consequently, the majority of infectious particles are produced from integrated DNA. With the use of RT-PCR techniques, cultured B cells isolated from blood or jejunal or ileal Peyer's patches consistently produced genomic and subgenomic RNA following BLV infection. Thus, BLV infection and replication were not limited by any of the target B-cell populations that were evaluated.
The variety of culture systems used throughout the present investigation facilitated an analysis of the interaction between BLV and B cells. With long-term B-cell cultures, it was possible to analyze the persistence of BLV infection. Detection of BLV transcripts at 60 days p.i. confirmed that BLV infection could persist for a prolonged period in the B-cell cultures. Experiments with cloned sheep B cells provided conclusive proof of direct B-cell infection by BLV and clearly demonstrated that BLV infection was not restricted to sIgM+ B cells. The data from cloned B cells also confirmed that BLV replication could occur in a pure B-cell population. This observation supports the conclusion that BLV transcription is not T-cell dependent (20). The effect of BLV infection on B-cell survival and proliferation varied with culture conditions and the target B-cell population. This suggests that external stimuli and the state of B-cell activation may significantly influence the fate of a B cell following BLV infection. For example, the reduced level of cell death in iPfB-cell cultures costimulated with human IL-2 and -4 might be consistent with a previous report that BLV infection protects blood lymphocytes from ex vivo spontaneous apoptosis in sheep (4). Thus, the development of an in vitro model for BLV infection of B cells provides a novel approach to investigating the interaction between a retrovirus and B cells and to identifying factors that might influence this interaction.
Finally, the injection of BLV-infected B cells into naive sheep
provided a sensitive method for detecting the production of functional
viral particles. Inoculation with FLK-exposed B cells induced
seroconversion, and provirus was first detected in blood samples at 3 weeks p.i. A gradual increase in virus load and antibody titers over a
1-year period confirmed that viral replication was occurring in the
challenged animals. The 3-week delay in detecting provirus in blood and
a gradual increase in virus load ruled out the possibility that
inoculated, allogeneic B cells were the source of the provirus
detected. Furthermore, it was previously shown that ovine B cells
costimulated with murine CD154 and
-chain-common cytokines die
within 5 to 7 days after being deprived of these stimuli
(13). The in vivo infection experiments with BLV-infected B-cell cultures proved that infection-competent progeny virus were
produced following BLV infection of ovine B-cell cultures. Thus, the
present investigation conclusively demonstrated that BLV can infect and
replicate in both immature and mature ovine B cells. Ovine B-cell
cultures permissive for BLV infection might provide a very useful model
for investigating the leukemogenic process during B-cell transformation
by a retrovirus.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by funds from the Fonds MEDIC, the Fonds National de la Recherche Scientifique, the Fondation BEKALES, the Fondation Rose et Jean Hoguet, NATO Collaborative Research grant 960219, the Alberta Agriculture Research Institute (AARI), and the Saskatchewan Health Services Utilization and Research Commission (HSURC).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institut J. Bordet, Hématologie Expérimentale, 121, Blvd. de Waterloo, 1000 Brussels, Belgium. Phone: (32) 2 541 37 39. Fax: (32) 2 541 34 53. E-mail: anne_vandenbroeke{at}compuserve.com.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Birkebak, T. A., G. H. Palmer, W. C. Davis, D. P. Knowles, and T. F. McElwain. 1994. Association of GP51 expression and persistent CD5+ B-lymphocyte expansion with lymphomagenesis in bovine leukemia virus infected sheep. Leukemia 8:1890-1899[Medline]. |
| 2. | Burny, A., L. Willems, I. Callebaut, E. Adam, I. Cludts, F. Dequiedt, L. Droogmans, C. Grimonpont, P. Kerkhofs, M. Mammerickx, D. Portetelle, A. Van den Broeke, and R. Kettmann. 1994. Bovine leukemia virus: biology and mode of transformation, p. 213-234. In A. C. Minson, J. C. Neil, and M. A. McRae (ed.), Viruses and cancer. Cambridge University Press, Cambridge, U.K. |
| 3. | Cara, A., and M. S. J. Reitz. 1997. New insight on the role of extrachromosomal retroviral DNA. Leukemia 11:1395-1399[CrossRef][Medline]. |
| 4. | Dequiedt, F., E. Hanon, P. Kerkhofs, P. P. Pastoret, D. Portetelle, A. Burny, R. Kettmann, and L. Willems. 1997. Both wild-type and strongly attenuated bovine leukemia viruses protect peripheral blood mononuclear cells from apoptosis. J. Virol. 71:630-639[Abstract]. |
| 5. |
Derse, D.
1987.
Bovine leukemia virus transcription is controlled by a virus-encoded trans-acting factor and by cis-acting response elements.
J. Virol.
61:2462-2471 |
| 6. |
Derse, D., and L. Martarano.
1990.
Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity.
J. Virol.
64:401-405 |
| 7. | Domenech, A., L. Llames, J. Goyache, G. Suarez, and E. Gomez-Lucia. 1997. Macrophages infected with bovine leukaemia virus (BLV) induce humoral response in rabbits. Vet. Immunol. Immunopathol. 58:309-320[CrossRef][Medline]. |
| 8. | Dudler, L., P. Griebel, and W. Hein. 1997. Separation of mononuclear cells from blood, p. 2075-2078. In I. Lefkovits (ed.), Immunological methods manual. Academic Press, London, U.K. |
| 9. | Felber, B. K., D. Derse, A. Athanassopoulos, M. Campbell, and G. N. Pavlakis. 1989. Cross-activation of the Rex proteins of HTLV-I and BLV and of the Rev protein of HIV-1 and nonreciprocal interactions with their RNA responsive elements. New Biol. 1:318-328[Medline]. |
| 10. |
Franchini, G.
1995.
Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection.
Blood
86:3619-3639 |
| 11. | Gallo, R. C., and L. S. Nerurkar. 1989. Human retroviruses: their role in neoplasia and immunodeficiency. Ann. N.Y. Acad. Sci. 567:82-94[Abstract]. |
| 12. | Griebel, P. 1997. Culture of ileal Peyer's patches B cells, p. 2079-2086. In I. Lefkovits (ed.), Immunological methods manual. Academic Press, London, U.K. |
| 13. |
Griebel, P.,
T. Beskorwayne,
A. Van den Broeke, and G. Ferrari.
1999.
CD40 signaling induces B cell responsiveness to multiple members of the gamma chain-common cytokine family.
Int. Immunol.
11:1139-1147 |
| 14. |
Griebel, P., and G. Ferrari.
1995.
CD40 signalling in ileal Peyer's patch B cells: implications for T cell-dependent antigen selection.
Int. Immunol.
7:369-379 |
| 15. | Griebel, P. J., T. Beskorwayne, D. L. Godson, Y. Popowych, and W. Hein. 2000. Cloning non-transformed sheep B cells. J. Immunol. Methods 237:19-28[CrossRef][Medline]. |
| 16. | Griebel, P. J., W. C. Davis, and J. D. Reynolds. 1992. An analysis of the growth and differentiation of B cells isolated from follicles of the ileal Peyer's patch of sheep. Immunology 75:601-607[Medline]. |
| 17. | Griebel, P. J., and G. Ferrari. 1994. Evidence for a stromal cell-dependent, self-renewing B cell population in lymphoid follicles of the ileal Peyer's patch of sheep. Eur. J. Immunol. 24:401-409[Medline]. |
| 18. | Griebel, P. J., P. Ghia, U. Grawunder, and G. Ferrari. 1996. A novel molecular complex expressed on immature B cells: a possible role in T cell-independent B cell development. Dev. Immunol. 5:67-78[Medline]. |
| 19. | Heeney, J. L., P. J. Valli, R. M. Jacobs, and V. E. Valli. 1992. Evidence for bovine leukemia virus infection of peripheral blood monocytes and limited antigen expression in bovine lymphoid tissue. Lab. Investig. 66:608-617[Medline]. |
| 20. | Jensen, W. A., S. E. Sheehy, M. H. Fox, W. C. Davis, and G. L. Cockerell. 1990. In vitro expression of bovine leukemia virus in isolated B-lymphocytes of cattle and sheep. Vet. Immunol. Immunopathol. 26:333-342[CrossRef][Medline]. |
| 21. |
Kerkhofs, P.,
H. Heremans,
A. Burny,
R. Kettmann, and L. Willems.
1998.
In vitro and in vivo oncogenic potential of bovine leukemia virus G4 protein.
J. Virol.
72:2554-2559 |
| 22. | Kettmann, R., A. Burny, I. Callebaut, L. Droogmans, M. Mammerickx, L. Willems, and D. Portetelle. 1994. Bovine leukemia virus, p. 39-81. In J. A. Levy (ed.), The retroviridae. Plenum Press, New York, N.Y. |
| 23. |
Kettmann, R.,
Y. Cleuter,
D. Gregoire, and A. Burny.
1985.
Role of the 3' long open reading frame region of bovine leukemia virus in the maintenance of cell transformation.
J. Virol.
54:899-901 |
| 24. | Kettmann, R., M. Mammerickx, D. Portetelle, D. Gregoire, and A. Burny. 1984. Experimental infection of sheep and goat with bovine leukemia virus: localization of proviral information on the target cells. Leukocyte Res. 8:937-944. |
| 25. |
Lewis, P. F., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516 |
| 26. | Mammerickx, M., R. Palm, D. Portetelle, and A. Burny. 1988. Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease. Leukemia 2:103-107[Medline]. |
| 27. | Meirom, R., S. Moss, and J. Brenner. 1997. Bovine leukemia virus-gp51 antigen expression is associated with CD5 and IgM markers on infected lymphocytes. Vet. Immunol. Immunopathol. 59:113-119[CrossRef][Medline]. |
| 28. |
Milan, D., and J. F. Nicolas.
1991.
Activator-dependent and activator-independent defective recombinant retroviruses from bovine leukemia virus.
J. Virol.
65:1938-1945 |
| 29. | Mirsky, M. L., C. A. Olmstead, Y. Da, and H. A. Lewin. 1996. The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection. J. Virol. 70:2178-2183[Abstract]. |
| 30. | Motyka, B., and J. D. Reynolds. 1991. Apoptosis is associated with the extensive B cell death in the sheep ileal Peyer's patch and the chicken bursa of Fabricius: a possible role in B cell selection. Eur. J. Immunol. 21:1951-1958[Medline]. |
| 31. | Murakami, K., Y. Aida, R. Kageyama, S. Numakunai, K. Ohshima, K. Okada, and Y. Ikawa. 1994. Immunopathologic study and characterization of the phenotype of transformed cells in sheep with bovine leukemia virus-induced lymphosarcoma. Am. J. Vet. Res. 55:72-80[Medline]. |
| 32. |
Murakami, K.,
K. Okada,
Y. Ikawa, and Y. Aida.
1994.
Bovine leukemia virus induces CD5 B cell lymphoma in sheep despite temporarily increasing CD5+ B cells in asymptomatic stage.
Virology
202:458-465[CrossRef][Medline].
|
| 33. | Portetelle, D., M. Mammerickx, and A. Burny. 1989. Use of two monoclonal antibodies in an ELISA test for the detection of antibodies to bovine leukaemia virus envelope protein gp51. J. Virol. Methods 23:211-222[CrossRef][Medline]. |
| 34. |
Powers, M. A., and K. Radke.
1992.
Activation of bovine leukemia virus transcription in lymphocytes from infected sheep: rapid transition through early to late gene expression.
J. Virol.
66:4769-4777 |
| 35. |
Pozzatti, R.,
J. Vogel, and G. Jay.
1990.
The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells.
Mol. Cell. Biol.
10:413-417 |
| 36. |
Reyes, R. A., and G. L. Cockerell.
1996.
Unintegrated bovine leukemia virus DNA: association with viral expression and disease.
J. Virol.
70:4961-4965 |
| 37. |
Rovnak, J.,
A. L. Boyd,
J. W. Casey,
M. A. Gonda,
W. A. Jensen, and G. L. Cockerell.
1993.
Pathogenicity of molecularly cloned bovine leukemia virus.
J. Virol.
67:7096-7105 |
| 38. |
Sagata, N.,
T. Yasunaga,
J. Tsuzuku-Kawamura,
K. Ohishi,
Y. Ogawa, and Y. Ikawa.
1985.
Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses.
Proc. Natl. Acad. Sci. USA
82:677-681 |
| 39. |
Schwartz, I.,
A. Bensaid,
B. Polack,
B. Perrin,
M. Berthelemy, and D. Levy.
1994.
In vivo leukocyte tropism of bovine leukemia virus in sheep and cattle.
J. Virol.
68:4589-4596 |
| 40. |
Van den Broeke, A.,
C. Bagnis,
M. Ciesiolka,
Y. Cleuter,
H. Gelderblom,
P. Kerkhofs,
P. Griebel,
P. Mannoni, and A. Burny.
1999.
In vivo rescue of a silent tax-deficient bovine leukemia virus from a tumor-derived ovine B-cell line by recombination with a retrovirally transduced wild-type tax gene.
J. Virol.
73:1054-1065 |
| 41. |
Van den Broeke, A.,
Y. Cleuter,
G. Chen,
D. Portetelle,
M. Mammerickx,
D. Zagury,
M. Fouchard,
L. Coulombel,
R. Kettmann, and A. Burny.
1988.
Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells.
Proc. Natl. Acad. Sci. USA
85:9263-9267 |
| 42. | Van den Broeke, A., Y. Cleuter, L. Droogmans, A. Burny, and R. Kettmann. 1997. Isolation and culture of B lymphoblastoid cell lines from bovine leukemia virus-induced tumors, p. 2127-2132. In J. Lefkovits (ed.), Immunological methods manual. Academic Press, London, U.K. |
| 43. | Van den Broeke, A., Y. Cleuter, D. Portetelle, M. Mammerickx, R. Kettmann, and A. Burny. 1990. Viral expression in bovine leukemia virus-induced tumor cells. Dev. Biol. Stand. 72:77-80[Medline]. |
| 44. | Van Der Maaten, M. J., and J. M. Miller. 1976. Replication of bovine leukemia virus in monolayer cell cultures. Bibl. Haematol. 43:360-362. |
| 45. | Vernau, W., R. M. Jacobs, V. E. Valli, and J. L. Heeney. 1997. The immunophenotypic characterization of bovine lymphomas. Vet. Pathol. 34:222-225[Abstract]. |
| 46. | Willems, L., H. Heremans, G. Chen, D. Portetelle, A. Billiau, A. Burny, and R. Kettmann. 1990. Cooperation between bovine leukaemia virus transactivator protein and Ha-ras oncogene product in cellular transformation. EMBO J. 9:1577-1581[Medline]. |
| 47. | Willems, L., P. Kerkhofs, A. Burny, M. Mammerickx, and R. Kettmann. 1995. Lack of LTR and ENV genetic variation during bovine leukemia virus-induced leukemogenesis. Virology 206:769-772[CrossRef][Medline]. |
| 48. |
Willems, L.,
P. Kerkhofs,
F. Dequiedt,
D. Portetelle,
M. Mammerickx,
A. Burny, and R. Kettmann.
1994.
Attenuation of bovine leukemia virus by deletion of R3 and G4 open reading frames.
Proc. Natl. Acad. Sci. USA
91:11532-11536 |
| 49. |
Willems, L.,
R. Kettmann,
F. Dequiedt,
D. Portetelle,
V. Voneche,
I. Cornil,
P. Kerkhofs,
A. Burny, and M. Mammerickx.
1993.
In vivo infection of sheep by bovine leukemia virus mutants.
J. Virol.
67:4078-4085 |
| 50. | Willems, L., D. Portetelle, P. Kerkhofs, G. Chen, A. Burny, M. Mammerickx, and R. Kettmann. 1992. In vivo transfection of bovine leukemia provirus into sheep. Virology 189:775-777[CrossRef][Medline]. |
| 51. | Yip, M. T., and I. S. Chen. 1990. Modes of transformation by the human T-cell leukemia viruses. Mol. Biol. Med. 7:33-44[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|